Declines in muscle protein synthesis account for short-term muscle disuse atrophy in humans in the absence of increased muscle protein breakdown.
Atrophy
Immobilization
Muscle
Protein breakdown
Protein synthesis
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
30
03
2022
received:
05
11
2021
accepted:
04
04
2022
pubmed:
24
5
2022
medline:
26
8
2022
entrez:
23
5
2022
Statut:
ppublish
Résumé
We determined the short-term (i.e. 4 days) impacts of disuse atrophy in relation to muscle protein turnover [acute fasted-fed muscle protein synthesis (MPS)/muscle protein breakdown (MPB) and integrated MPS/estimated MPB]. Healthy men (N = 9, 22 ± 2 years, body mass index 24 ± 3 kg m Immobilization decreased TLM [pre: 7477 ± 1196 g, post: 7352 ± 1209 g (P < 0.01)], MT [pre: 2.67 ± 0.50 cm, post: 2.55 ± 0.51 cm (P < 0.05)], and strength [pre: 260 ± 43 N m, post: 229 ± 37 N m (P < 0.05)] with no change in control legs. Integrated MPS decreased in immob vs. control legs [control: 1.55 ± 0.21% day Human skeletal muscle disuse atrophy is driven by declines in MPS, not increases in MPB. Pro-anabolic therapies to mitigate disuse atrophy would likely be more effective than therapies aimed at attenuating protein degradation.
Sections du résumé
BACKGROUND
We determined the short-term (i.e. 4 days) impacts of disuse atrophy in relation to muscle protein turnover [acute fasted-fed muscle protein synthesis (MPS)/muscle protein breakdown (MPB) and integrated MPS/estimated MPB].
METHODS
Healthy men (N = 9, 22 ± 2 years, body mass index 24 ± 3 kg m
RESULTS
Immobilization decreased TLM [pre: 7477 ± 1196 g, post: 7352 ± 1209 g (P < 0.01)], MT [pre: 2.67 ± 0.50 cm, post: 2.55 ± 0.51 cm (P < 0.05)], and strength [pre: 260 ± 43 N m, post: 229 ± 37 N m (P < 0.05)] with no change in control legs. Integrated MPS decreased in immob vs. control legs [control: 1.55 ± 0.21% day
CONCLUSIONS
Human skeletal muscle disuse atrophy is driven by declines in MPS, not increases in MPB. Pro-anabolic therapies to mitigate disuse atrophy would likely be more effective than therapies aimed at attenuating protein degradation.
Identifiants
pubmed: 35606155
doi: 10.1002/jcsm.13005
pmc: PMC9397550
doi:
Substances chimiques
Muscle Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2005-2016Subventions
Organisme : Medical Research Council
ID : MR/P021220/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R502364/1
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E753-64
pubmed: 12217893
J Cachexia Sarcopenia Muscle. 2014 Mar;5(1):19-25
pubmed: 24009031
Med Sci Sports Exerc. 2020 Apr;52(4):944-954
pubmed: 31688656
EMBO J. 2008 Apr 23;27(8):1266-76
pubmed: 18354498
FASEB J. 2018 Jan;32(1):265-275
pubmed: 28899879
Acta Physiol (Oxf). 2014 Mar;210(3):600-11
pubmed: 24168489
Amino Acids. 2010 May;38(5):1533-9
pubmed: 19882215
FASEB J. 2019 Mar;33(3):4586-4597
pubmed: 30629458
J Physiol. 2017 May 1;595(9):2873-2882
pubmed: 27610950
J Physiol. 2014 Dec 15;592(24):5341-3
pubmed: 25512435
J Clin Endocrinol Metab. 2013 Jun;98(6):2604-12
pubmed: 23589526
J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2005-2016
pubmed: 35606155
Am J Clin Nutr. 2010 Nov;92(5):1080-8
pubmed: 20844073
FASEB J. 2021 Sep;35(9):e21830
pubmed: 34342902
Am J Physiol. 1996 Apr;270(4 Pt 1):E627-33
pubmed: 8928769
Acta Physiol (Oxf). 2016 Jan;216(1):15-41
pubmed: 26010896
J Appl Physiol (1985). 2008 Oct;105(4):1380-1; author reply 1382-3
pubmed: 18838517
Am J Physiol Endocrinol Metab. 2012 May 15;302(9):E1113-22
pubmed: 22338078
J Appl Physiol (1985). 2008 Sep;105(3):902-6
pubmed: 18535133
Am J Physiol Endocrinol Metab. 2020 Feb 1;318(2):E117-E130
pubmed: 31743039
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
Biochim Biophys Acta. 1975 Nov 18;414(1):71-84
pubmed: 811266
Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E595-604
pubmed: 18577697
J Physiol. 2007 Nov 15;585(Pt 1):241-51
pubmed: 17901116
Front Physiol. 2016 Aug 25;7:361
pubmed: 27610086
FASEB J. 2015 Nov;29(11):4485-96
pubmed: 26169934
Am J Physiol Endocrinol Metab. 2014 Mar 1;306(5):E571-9
pubmed: 24381002
J Clin Endocrinol Metab. 2013 Dec;98(12):4872-81
pubmed: 24108315
Scand J Med Sci Sports. 2018 Mar;28(3):846-853
pubmed: 28805932
Am J Physiol Endocrinol Metab. 2016 Jan 15;310(2):E137-47
pubmed: 26578714
Pflugers Arch. 2020 Feb;472(2):281-292
pubmed: 32025814
PLoS One. 2012;7(12):e51238
pubmed: 23284670
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1056-65
pubmed: 25827594
Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E895-907
pubmed: 23423170
Pharm Stat. 2009 Apr-Jun;8(2):163-9
pubmed: 18416448
Am J Physiol. 1996 May;270(5 Pt 1):E759-67
pubmed: 8967463
Influenza Other Respir Viruses. 2018 Jan;12(1):171-182
pubmed: 28991409
J Appl Physiol (1985). 2006 Oct;101(4):1136-48
pubmed: 16763108
J Nutr. 2013 Mar;143(3):307-14
pubmed: 23343676
Acta Physiol (Oxf). 2007 Oct;191(2):147-59
pubmed: 17655736
J Am Med Dir Assoc. 2019 Jan;20(1):35-42
pubmed: 30108034
JAMA. 2013 Oct 16;310(15):1591-600
pubmed: 24108501
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1276-1294
pubmed: 31568675
J Appl Physiol (1985). 2009 Jul;107(1):34-8
pubmed: 19390002
Front Nutr. 2019 May 24;6:75
pubmed: 31179284
J Appl Physiol (1985). 2010 Sep;109(3):721-7
pubmed: 20538844
J Physiol. 2008 Dec 15;586(24):6049-61
pubmed: 18955382